Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomezol for Non-erosive Gastroesophageal Reflux Disease
NCT03436914Completed
- Sponsor
- Yonsei University
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Espazole in Non-erosive Gastroesophageal Reflux Disease (NERD), sponsored by Yonsei University. Primary endpoint: Proportion of PAGI-SYM score (0-2) patients after 8 weeks of PPI(Esomezol). Started Sep 2018; status: completed.
02
Drugs
Espazole
03
Conditions
Non-erosive Gastroesophageal Reflux Disease (NERD)
Beyond the preview
Go deeper on NCT03436914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436914.